Comparative Efficacy of Alpha Hydroxy Acids With and Without Nanocarriers Versus Calcipotriol Plus Betamethasone in Treatment of Plaque Psoriasis

NCT07816575 | Completed

• 1 other identifier: AHAs,Nanocarriers in psoriasis
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this double blind comparative clinical study is to evaluate the efficacy of AHAs combined with nanocarriers and their use as a non steroidal alternative drug for long term management of plaque psoriasis

Conditions

Psoriasis

Outcome Measures

Primary Outcomes (1)

• Percentage Change in PASI Score.

  Reduction in PASI score from baseline to week 8.

  Baseline and 8 weeks

Secondary Outcomes (1)

• Dermatology Life Quality Index (DLQI)

  Baseline and 8 weeks).

Other Outcomes (1)

• Frequency of Adverse Events

  Throughout the study period (up to 8 weeks)

Study Arms (4)

Alpha Hydroxy Acids with Nanocarriers Group

EXPERIMENTAL

Patients received Alpha Hydroxy Acids formulated with nanocarriers.

Drug: Alpha Hydroxy Acids with nanocarriers

Alpha Hydroxy Acids Group.

EXPERIMENTAL

Patients received Alpha Hydroxy Acids only.

Drug: Alpha Hydroxy Acids only.

Calcipotriol plus betamethasone Group.

ACTIVE COMPARATOR

Patients received calcipotriol plus betamethasone.

Drug: Calcipotriol plus betamethasone

Placebo Group

PLACEBO COMPARATOR

Patients received placebo comparator.

Other: Placebo.

Interventions

Alpha Hydroxy Acids with nanocarriers DRUG

Topical Alpha Hydroxy Acids formulated with nanocarriers applied to psoriatic plaques.

Alpha Hydroxy Acids with Nanocarriers Group

Alpha Hydroxy Acids only. DRUG

Topical Alpha Hydroxy Acids only applied to psoriatic plaques.

Alpha Hydroxy Acids Group.

Calcipotriol plus betamethasone DRUG

Topical calcipotriol plus betamethasone ointment applied to psoriatic plaques.

Calcipotriol plus betamethasone Group.

Placebo. OTHER

Vehicle control / Placebo topical application applied to psoriatic plaques

Placebo Group

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age from18-65 years old.
• Denovo psoriatic patients and patients with no psoriasis therapy in the previous two months.

You may not qualify if:

• Severe irritation and highly inflamed skin.
• Pregnant and lactating females.
• Patients with acute renal insufficiency.
• Face, flexural and groin lesions.

Sponsors & Collaborators

• Al-Azhar University: lead

Study Sites (1)

Al-Hussien and cairo dermatology Hospital

Cairo, Egypt

Location

MeSH Terms

Conditions

Psoriasis

Interventions

calcipotriene; Betamethasone

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Pregnadienetriols; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Steroids, Fluorinated

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident

Study Record Dates

• First Submitted: September 8, 2026
• First Posted: September 11, 2026
• Study Start: March 15, 2024
• Primary Completion: July 3, 2025
• Study Completion: September 10, 2025
• Last Updated: September 11, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)